Evidence map›Paper›PMID 31572426›Full record

ArticleDementia and geriatric cognitive disorders extra

Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan.

Kengo Ueda, Sadao Katayama, Tetsuaki Arai, Nobuo Furuta, Shinichiro Ikebe, Yoshinori Ishida, Kiyoshi Kanaya, Shinji Ouma, Hirofumi Sakurai, Masato Sugitani and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dementia and geriatric cognitive disorders extra. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kengo UedaNovartis Pharma K.K., Tokyo, Japan.
Sadao KatayamaKatayama Medical Clinic, Okayama, Japan.
Tetsuaki AraiFaculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Nobuo FurutaYokufukai Hospital, Tokyo, Japan.
Shinichiro IkebeIkebe Clinic, Shizuoka, Japan.
Yoshinori IshidaTakeda General Hospital, Fukushima, Japan.
Kiyoshi KanayaHachioji Medical Center, Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.
Shinji OumaDepartment of Neurology, Fukuoka University, Fukuoka, Japan.
Hirofumi SakuraiDepartment of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.
Masato SugitaniSagamihara Kyodo Hospital, Kanagawa, Japan.
Makio TakahashiDepartment of Neurology, Osaka Red Cross Hospital, Osaka, Japan.
Toshihisa TanakaDepartment of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan.
Norifumi TsunoDepartment of Neuropsychiatry, Kagawa University School of Medicine, Kagawa, Japan.
Yosuke WakutaniDepartment of Neurology, Kurashiki Heisei Hospital, Okayama, Japan.
Ankita ShekhawatNovartis Healthcare Pvt. Ltd., Data Sciences, SSP, PLS, Hyderabad, India.
Ayan Das GuptaNovartis Healthcare Pvt. Ltd., Data Sciences, SSP, PLS, Hyderabad, India.
Kazuki KiyoseNovartis Pharma K.K., Tokyo, Japan.
Kazuhiro ToriyamaNovartis Pharma K.K., Tokyo, Japan.
Yu NakamuraDepartment of Neuropsychiatry, Kagawa University School of Medicine, Kagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFew studies have investigated treatment options for patients with Alzheimer's disease (AD) showing a poor response to oral cholinesterase inhibitors (ChEIs) in Japan.

objectiveTo investigate the efficacy and safety of switching from oral ChEIs to rivastigmine transdermal patch in patients with AD.

methodsIn this multicenter, open-label, phase IV study in outpatient clinics in Japan, patients with mild-moderate AD who had a poor response to or experienced difficulty in continuing donepezil or galantamine were switched to rivastigmine transdermal patch (5 cm

resultsA total of 118 patients were enrolled and switched to rivastigmine, of which 102 completed the 24-week study. The MMSE total score was essentially unchanged during the study, with a least-square mean change (SD) of -0.35 (2.64) at week 24 (

conclusionWithin-class switching from an oral ChEI to rivastigmine transdermal patch might be an efficacious and tolerable option for AD patients showing a poor or limited response to a prior oral ChEI.

Indexed as

Alzheimer's diseaseCholinesterase inhibitorsRivastigmine transdermal patchSwitching

Identifiers

PMID31572426
PMCPMC6751467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.